BRPI0812904A2 - COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA - Google Patents

COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA

Info

Publication number: BRPI0812904A2
Authority: BR; Brazil
Prior art keywords: cortisol; inhibition; same; spyrocycles; 11ßhsd1
Prior art date: 2007-06-21

Application number

BRPI0812904-5A2A

Other languages

English (en)

Inventor

Wenqing Yao

Jincong Zhuo

Colin Zhang

Original Assignee

Incyte Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-21

Filing date

2008-06-20

Publication date

2014-12-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812904(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-20 Application filed by Incyte Corp filed Critical Incyte Corp

2014-12-09 Publication of BRPI0812904A2 publication Critical patent/BRPI0812904A2/pt

Links

JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 title 6
229960000890 hydrocortisone Drugs 0.000 title 3
230000005764 inhibitory process Effects 0.000 title 2
238000006243 chemical reaction Methods 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)

BRPI0812904-5A2A 2007-06-21 2008-06-20 COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA BRPI0812904A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94548707P	2007-06-21	2007-06-21
PCT/US2008/067637 WO2008157752A1 (en)	2007-06-21	2008-06-20	Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1

Publications (1)

Publication Number	Publication Date
BRPI0812904A2 true BRPI0812904A2 (pt)	2014-12-09

Family

ID=39731144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812904-5A2A BRPI0812904A2 (pt)	2007-06-21	2008-06-20	COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA

Country Status (30)

Country	Link
US (4)	US8278318B2 (pt)
EP (3)	EP2173750B9 (pt)
JP (2)	JP5364702B2 (pt)
KR (1)	KR101554471B1 (pt)
CN (1)	CN101815716B (pt)
AR (1)	AR067090A1 (pt)
AU (1)	AU2008265656B2 (pt)
BR (1)	BRPI0812904A2 (pt)
CA (1)	CA2691150C (pt)
CL (1)	CL2008001839A1 (pt)
CO (1)	CO6150151A2 (pt)
CR (1)	CR11183A (pt)
CY (2)	CY1113212T1 (pt)
DK (2)	DK2540723T3 (pt)
EA (1)	EA016017B1 (pt)
EC (1)	ECSP109844A (pt)
ES (2)	ES2390937T3 (pt)
GE (1)	GEP20135754B (pt)
HR (2)	HRP20120772T1 (pt)
IL (1)	IL202842A (pt)
MX (1)	MX2009014274A (pt)
NZ (1)	NZ582524A (pt)
PL (2)	PL2540723T3 (pt)
PT (2)	PT2540723E (pt)
RS (2)	RS52519B9 (pt)
SI (2)	SI2173750T1 (pt)
TW (1)	TWI428340B (pt)
UA (1)	UA98651C2 (pt)
WO (1)	WO2008157752A1 (pt)
ZA (1)	ZA201000233B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI350168B (en) *	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
MXPA06014572A (es) *	2004-06-24	2007-03-12	Incyte Corp	Compuestos amido y su uso como farmaceuticos.
US20060009491A1 (en) *	2004-06-24	2006-01-12	Incyte Corporation	Amido compounds and their use as pharmaceuticals
WO2006012226A2 (en) *	2004-06-24	2006-02-02	Incyte Corporation	N-substituted piperidines and their use as pharmaceuticals
EP1768954A4 (en) *	2004-06-24	2008-05-28	Incyte Corp	2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
EA200700251A1 (ru) *	2004-08-10	2007-08-31	Инсайт Корпорейшн	Амидосоединения и их применение в качестве фармацевтических средств
US8110581B2 (en)	2004-11-10	2012-02-07	Incyte Corporation	Lactam compounds and their use as pharmaceuticals
WO2007101270A1 (en) *	2006-03-02	2007-09-07	Incyte Corporation	MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US8088776B2 (en)	2006-04-21	2012-01-03	Eli Lilly And Company	Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
NZ571175A (en)	2006-04-21	2011-10-28	Lilly Co Eli	Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0710273A2 (pt)	2006-04-21	2011-08-09	Lilly Co Eli	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
ATE472542T1 (de)	2006-04-24	2010-07-15	Lilly Co Eli	11-beta-hydroxysteroid-dehydrogenase-1-hemmer
CA2649650C (en)	2006-04-24	2014-01-14	Eli Lilly And Company	Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ATE543798T1 (de)	2006-04-24	2012-02-15	Lilly Co Eli	Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
US7968585B2 (en)	2006-04-25	2011-06-28	Eli Lilly And Company	Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2021337B1 (en)	2006-04-25	2010-01-13	Eli Lilly And Company	Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244863B2 (en)	2006-04-25	2012-01-19	Eli Lilly And Company	Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2008013844A (es)	2006-04-28	2008-11-10	Lilly Co Eli	Pirrolidinonas substituidas con pieridinilo como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1.
JP2009537564A (ja) *	2006-05-17	2009-10-29	インサイト・コーポレイション	１１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの複素環阻害剤およびそれを用いる方法
CL2008001839A1 (es) *	2007-06-21	2009-01-16	Incyte Holdings Corp	Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
AR074466A1 (es)	2008-12-05	2011-01-19	Sanofi Aventis	Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
US8507493B2 (en)	2009-04-20	2013-08-13	Abbvie Inc.	Amide and amidine derivatives and uses thereof
WO2011068927A2 (en) *	2009-12-04	2011-06-09	Abbott Laboratories	11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015123424A1 (en)	2014-02-13	2015-08-20	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
LT3105218T (lt)	2014-02-13	2019-12-10	Incyte Corp	Ciklopropilaminai kaip lsd1 inhibitoriai
EP3392244A1 (en)	2014-02-13	2018-10-24	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
WO2016007736A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyrazines as lsd1 inhibitors
WO2016007731A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9758523B2 (en)	2014-07-10	2017-09-12	Incyte Corporation	Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EA201792205A1 (ru)	2015-04-03	2018-02-28	Инсайт Корпорейшн	Гетероциклические соединения как ингибиторы lsd1
DK3334709T3 (da)	2015-08-12	2025-02-03	Incyte Holdings Corp	Salte af en lsd1-hæmmer
EP3235813A1 (en)	2016-04-19	2017-10-25	Cidqo 2012, S.L.	Aza-tetra-cyclo derivatives
CA3021678A1 (en)	2016-04-22	2017-10-26	Incyte Corporation	Formulations of an lsd1 inhibitor
US10435841B2 (en) *	2016-05-03	2019-10-08	GranBio Intellectual Property Holdings, LLC	Nanocellulose-reinforced corrugated medium
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4439606A (en) *	1982-05-06	1984-03-27	American Cyanamid Company	Antiatherosclerotic 1-piperazinecarbonyl compounds
US5206240A (en) *	1989-12-08	1993-04-27	Merck & Co., Inc.	Nitrogen-containing spirocycles
US5852029A (en) *	1990-04-10	1998-12-22	Israel Institute For Biological Research	Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5102886A (en)	1990-10-12	1992-04-07	American Home Products Corporation	1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
DE4234295A1 (de) *	1992-10-12	1994-04-14	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2705343B1 (fr) *	1993-05-17	1995-07-21	Fournier Ind & Sante	Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2724656B1 (fr) *	1994-09-15	1996-12-13	Adir	Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2734265B1 (fr)	1995-05-17	1997-06-13	Adir	Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2736053B1 (fr) *	1995-06-28	1997-09-19	Sanofi Sa	Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
WO1997011940A1 (en)	1995-09-29	1997-04-03	Eli Lilly And Company	Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
WO2001030780A2 (en)	1999-10-27	2001-05-03	Cor Therapeutics, Inc.	Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
NZ519183A (en) *	1999-12-03	2005-02-25	Ono Pharmaceutical Co	Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient
EP1294358B1 (en)	2000-06-28	2004-08-18	Smithkline Beecham Plc	Wet milling process
US7294637B2 (en) *	2000-09-11	2007-11-13	Sepracor, Inc.	Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
WO2003000657A1 (en) *	2001-06-20	2003-01-03	Daiichi Pharmaceutical Co., Ltd.	Diamine derivatives
US6547958B1 (en) *	2001-07-13	2003-04-15	Chevron U.S.A. Inc.	Hydrocarbon conversion using zeolite SSZ-59
GB0118238D0 (en)	2001-07-26	2001-09-19	Smithkline Beecham Plc	Medicaments
GB0126292D0 (en)	2001-11-01	2002-01-02	Smithkline Beecham Plc	Compounds
NZ533567A (en)	2001-12-28	2007-06-29	Acadia Pharm Inc	Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
US6818772B2 (en) *	2002-02-22	2004-11-16	Abbott Laboratories	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
GB0213715D0 (en) *	2002-06-14	2002-07-24	Syngenta Ltd	Chemical compounds
AU2002354054A1 (en) *	2002-10-18	2004-05-04	Ono Pharmaceutical Co., Ltd.	Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
WO2004058727A1 (en)	2002-12-20	2004-07-15	Bayer Pharmaceuticals Corporation	Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004056744A1 (en)	2002-12-23	2004-07-08	Janssen Pharmaceutica N.V.	Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en)	2003-01-24	2005-02-01	Novartis Ag	Organic compounds
US7205318B2 (en)	2003-03-18	2007-04-17	Bristol-Myers Squibb Company	Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE602004027171D1 (de)	2003-04-11	2010-06-24	High Point Pharmaceuticals Llc	Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2005047286A1 (ja)	2003-11-13	2005-05-26	Ono Pharmaceutical Co., Ltd.	スピロ複素環化合物
BRPI0417687A (pt)	2003-12-19	2007-04-03	Pfizer	derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
AU2004309419A1 (en)	2003-12-23	2005-07-14	Arena Pharmaceuticals, Inc.	Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
AU2005219438B2 (en)	2004-03-03	2011-02-17	Chemocentryx, Inc.	Bicyclic and bridged nitrogen heterocycles
WO2005108359A1 (en)	2004-05-06	2005-11-17	Pfizer Inc.	Novel compounds of proline and morpholine derivatives
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
WO2006012226A2 (en)	2004-06-24	2006-02-02	Incyte Corporation	N-substituted piperidines and their use as pharmaceuticals
MXPA06014572A (es)	2004-06-24	2007-03-12	Incyte Corp	Compuestos amido y su uso como farmaceuticos.
EP1768954A4 (en)	2004-06-24	2008-05-28	Incyte Corp	2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
US20060009491A1 (en)	2004-06-24	2006-01-12	Incyte Corporation	Amido compounds and their use as pharmaceuticals
MXPA06014573A (es)	2004-06-24	2007-03-12	Incyte Corp	Compuestos amido y su uso como farmaceuticos.
CA2570694A1 (en) *	2004-06-24	2006-02-02	Incyte Corporation	Amido compounds and their use as pharmaceuticals
ATE509011T1 (de)	2004-06-28	2011-05-15	Hoffmann La Roche	Pyrimidinderivate als 11beta-hsd1-inhibitoren
EA200700251A1 (ru)	2004-08-10	2007-08-31	Инсайт Корпорейшн	Амидосоединения и их применение в качестве фармацевтических средств
BRPI0515931A (pt)	2004-09-29	2008-08-12	Hoffmann La Roche	compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
US7745427B2 (en)	2004-10-22	2010-06-29	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
SG161261A1 (en) *	2004-11-10	2010-05-27	Incyte Corp	Lactam compounds and their use as pharmaceuticals
US7170437B2 (en) *	2004-11-12	2007-01-30	U-Nav Microelectronics Corporation	Two-bit offset cancelling A/D converter with improved common mode rejection and threshold sensitivity
CN101103016A (zh) *	2004-11-18	2008-01-09	因塞特公司	11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
CA2594116A1 (en) *	2005-01-05	2006-07-13	Abbott Laboratories	Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1866285A1 (en) *	2005-03-03	2007-12-19	F. Hoffmann-Roche AG	1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
CA2621255A1 (en) *	2005-09-21	2007-04-05	Incyte Corporation	Amido compounds and their use as pharmaceuticals
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
AR057579A1 (es)	2005-11-23	2007-12-05	Merck & Co Inc	Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
EA200870019A1 (ru) *	2005-12-05	2008-12-30	Инсайт Корпорейшн	Лактамовые соединения и способы их применения
US7998959B2 (en) *	2006-01-12	2011-08-16	Incyte Corporation	Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
BRPI0707408A2 (pt) *	2006-01-31	2011-05-03	Incyte Corp	compostos de amido e seu uso como produtos farmacêuticos
WO2007101270A1 (en) *	2006-03-02	2007-09-07	Incyte Corporation	MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070208001A1 (en) *	2006-03-03	2007-09-06	Jincong Zhuo	Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2009535420A (ja) *	2006-05-01	2009-10-01	インサイト・コーポレイション	１１−βヒドロキシルステロイドデヒドロゲナーゼタイプ１のモジュレーターとしてのテトラ置換ウレア
JP2009537564A (ja) *	2006-05-17	2009-10-29	インサイト・コーポレイション	１１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの複素環阻害剤およびそれを用いる方法
JP4959794B2 (ja)	2006-07-05	2012-06-27	エフ．ホフマン−ラロシュアーゲー	１１β−ヒドロキシステロイドデヒドロゲナーゼ１型（１１β−ＨＳＤ１）の阻害剤としてのアルキルピリダジン誘導体
AU2007312391B2 (en)	2006-10-19	2012-06-21	F. Hoffmann-La Roche Ag	Imidazolone and imidazolidinone derivatives as 11b-HSD1 inhibitors for diabetes
CL2008001839A1 (es)	2007-06-21	2009-01-16	Incyte Holdings Corp	Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

2008
- 2008-06-19 CL CL2008001839A patent/CL2008001839A1/es unknown
- 2008-06-20 KR KR1020107001434A patent/KR101554471B1/ko not_active Expired - Fee Related
- 2008-06-20 WO PCT/US2008/067637 patent/WO2008157752A1/en not_active Ceased
- 2008-06-20 EA EA201070039A patent/EA016017B1/ru unknown
- 2008-06-20 EP EP08771573.6A patent/EP2173750B9/en active Active
- 2008-06-20 PL PL12178110T patent/PL2540723T3/pl unknown
- 2008-06-20 AR ARP080102645A patent/AR067090A1/es active IP Right Grant
- 2008-06-20 RS RS20120423A patent/RS52519B9/sr unknown
- 2008-06-20 US US12/143,427 patent/US8278318B2/en active Active
- 2008-06-20 PT PT12178110T patent/PT2540723E/pt unknown
- 2008-06-20 DK DK12178110.8T patent/DK2540723T3/en active
- 2008-06-20 SI SI200830779T patent/SI2173750T1/sl unknown
- 2008-06-20 TW TW097123261A patent/TWI428340B/zh not_active IP Right Cessation
- 2008-06-20 AU AU2008265656A patent/AU2008265656B2/en not_active Ceased
- 2008-06-20 EP EP12178110.8A patent/EP2540723B8/en active Active
- 2008-06-20 JP JP2010513441A patent/JP5364702B2/ja not_active Expired - Fee Related
- 2008-06-20 NZ NZ582524A patent/NZ582524A/en unknown
- 2008-06-20 CA CA2691150A patent/CA2691150C/en active Active
- 2008-06-20 EP EP14193608.8A patent/EP2918586A1/en not_active Withdrawn
- 2008-06-20 CN CN2008801022458A patent/CN101815716B/zh not_active Expired - Fee Related
- 2008-06-20 MX MX2009014274A patent/MX2009014274A/es active IP Right Grant
- 2008-06-20 UA UAA201000514A patent/UA98651C2/ru unknown
- 2008-06-20 PT PT08771573T patent/PT2173750E/pt unknown
- 2008-06-20 ES ES08771573T patent/ES2390937T3/es active Active
- 2008-06-20 GE GEAP200811654A patent/GEP20135754B/en unknown
- 2008-06-20 HR HRP20120772AT patent/HRP20120772T1/hr unknown
- 2008-06-20 PL PL08771573T patent/PL2173750T3/pl unknown
- 2008-06-20 DK DK08771573.6T patent/DK2173750T3/da active
- 2008-06-20 SI SI200831387T patent/SI2540723T1/sl unknown
- 2008-06-20 ES ES12178110T patent/ES2531056T3/es active Active
- 2008-06-20 RS RS20150103A patent/RS53839B1/sr unknown
- 2008-06-20 BR BRPI0812904-5A2A patent/BRPI0812904A2/pt not_active Application Discontinuation
2009
- 2009-12-20 IL IL202842A patent/IL202842A/en active IP Right Grant
- 2009-12-29 CO CO09148800A patent/CO6150151A2/es unknown
2010
- 2010-01-04 CR CR11183A patent/CR11183A/es unknown
- 2010-01-05 EC EC2010009844A patent/ECSP109844A/es unknown
- 2010-01-12 ZA ZA2010/00233A patent/ZA201000233B/en unknown
2012
- 2012-09-14 US US13/619,160 patent/US9006260B2/en active Active
- 2012-10-17 CY CY20121100974T patent/CY1113212T1/el unknown
2013
- 2013-07-17 JP JP2013148780A patent/JP5730956B2/ja not_active Expired - Fee Related
2015
- 2015-02-18 CY CY20151100167T patent/CY1116029T1/el unknown
- 2015-02-19 HR HRP20150197AT patent/HRP20150197T1/hr unknown
- 2015-04-07 US US14/680,745 patent/US9371323B2/en active Active
2016
- 2016-06-10 US US15/178,838 patent/US9873698B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2691150A1 (en)	2008-12-24
TW200909431A (en)	2009-03-01
WO2008157752A1 (en)	2008-12-24
CA2691150C (en)	2015-11-24
CO6150151A2 (es)	2010-04-20
ECSP109844A (es)	2010-02-26
TWI428340B (zh)	2014-03-01
CY1113212T1 (el)	2016-04-13
US8278318B2 (en)	2012-10-02
EP2540723A1 (en)	2013-01-02
JP2014015463A (ja)	2014-01-30
US20130018068A1 (en)	2013-01-17
UA98651C2 (ru)	2012-06-11
EP2173750B9 (en)	2017-04-05
HK1180325A1 (en)	2013-10-18
US20160280708A1 (en)	2016-09-29
SI2540723T1 (sl)	2015-04-30
ES2390937T3 (es)	2012-11-19
EP2540723B8 (en)	2015-01-28
RS52519B (sr)	2013-04-30
KR101554471B1 (ko)	2015-09-30
ZA201000233B (en)	2016-08-31
JP5730956B2 (ja)	2015-06-10
PL2173750T3 (pl)	2012-12-31
EA016017B1 (ru)	2012-01-30
PL2540723T3 (pl)	2015-07-31
JP5364702B2 (ja)	2013-12-11
IL202842A0 (en)	2010-06-30
GEP20135754B (en)	2013-02-25
IL202842A (en)	2014-11-30
CN101815716A (zh)	2010-08-25
ES2531056T3 (es)	2015-03-10
NZ582524A (en)	2012-05-25
HRP20120772T1 (hr)	2012-10-31
HRP20150197T1 (en)	2015-03-27
US20080318991A1 (en)	2008-12-25
SI2173750T1 (sl)	2012-11-30
US9873698B2 (en)	2018-01-23
EP2918586A1 (en)	2015-09-16
HK1143156A1 (en)	2010-12-24
EA201070039A1 (ru)	2010-06-30
EP2540723B1 (en)	2014-11-26
AR067090A1 (es)	2009-09-30
PT2173750E (pt)	2012-10-11
PT2540723E (pt)	2015-03-06
KR20100045440A (ko)	2010-05-03
JP2010530893A (ja)	2010-09-16
RS53839B1 (sr)	2015-06-30
MX2009014274A (es)	2010-03-25
EP2173750A1 (en)	2010-04-14
DK2540723T3 (en)	2015-01-19
CN101815716B (zh)	2012-12-26
DK2173750T3 (da)	2012-11-19
CY1116029T1 (el)	2017-01-25
EP2173750B1 (en)	2012-08-01
CR11183A (es)	2010-02-16
AU2008265656A1 (en)	2008-12-24
US9371323B2 (en)	2016-06-21
US20150210692A1 (en)	2015-07-30
US9006260B2 (en)	2015-04-14
RS52519B9 (sr)	2020-12-31
AU2008265656B2 (en)	2014-05-29
CL2008001839A1 (es)	2009-01-16

Legal Events

Date	Code	Title	Description
2015-11-17	B25G	Requested change of headquarter approved	Owner name: INCYTE CORPORATION (US)
2016-08-09	B25A	Requested transfer of rights approved	Owner name: INCYTE HOLDINGS CORPORATION (US)
2018-03-06	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B11E	Dismissal acc. art. 34 of ipl - requirements for examination incomplete
2020-09-24	B11T	Dismissal of application maintained [chapter 11.20 patent gazette]

Publication	Publication Date	Title
BRPI1009324A2 (pt)	2015-11-24	compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI1013421A2 (pt)	2016-04-05	composição parasticida tópica, e, uso de uma composição
BRPI0807146A2 (pt)	2014-04-15	Inibidores da atividade da akt
BRPI1009372A2 (pt)	2016-05-31	compostos, composição farmacêutica e respectivos usos
BRPI1009981A2 (pt)	2016-03-15	sistemas , métodos e composições para otimizar os enxertos enriquecidos de tecido e célula
BRPI0918496A2 (pt)	2019-09-24	composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
BRPI1013640A2 (pt)	2019-09-24	composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BR112012003709A2 (pt)	2016-04-05	compostos heterocíclicos e usos dos mesmos
BRPI0822337A2 (pt)	2015-06-16	Folatos, composições e usos dos mesmos
SV2011004019A (es)	2011-12-15	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BRPI0920927A2 (pt)	2019-09-24	derivados de azaquinolinona e usos dos mesmos
BRPI0924172A2 (pt)	2016-02-10	vitamina d promovendo proteção solar
BRPI0918360A2 (pt)	2017-10-10	composto, composição farmacêutica e usos de um composto
BRPI0915897A2 (pt)	2015-11-03	compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
IL214822A0 (en)	2011-11-30	Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
BRPI0908906A2 (pt)	2019-09-24	compostos heterocíclicos e usos dos mesmos
DK2139452T3 (da)	2011-11-14	Topisk polyaphronsammensætning med D-vitamin og corticosteroid
BRPI0908021A2 (pt)	2015-07-21	Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BR112013016179A2 (pt)	2018-07-10	inibidores seletivos da glicosidase e usos dos mesmos.
ZA201202489B (en)	2013-02-27	Novel heterocyclic acrylamides and their use as pharmaceuticals
BRPI0914343A2 (pt)	2016-07-26	composição, produto, uso da composição e método
BR112012001329A2 (pt)	2017-06-13	métodos para obter células com uma potência desejada, para tratar inflamação em um sujeito, para construir um banco de células, para descoberta de droga e para aumentar a potência de uma célula, e, composição.
DK2375907T3 (da)	2019-06-11	Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
IL200153A (en)	2016-11-30	History of Ethnon, including and use of pharmaceutical preparations
BRPI0818759A2 (pt)	2019-09-24	método para o tratamento de colheitas, solução de pulverização e uso de glicerol bruto derivado da produção de biodiesel na preparação de uma solução de pulverização